(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.74%) $83.23
(-1.16%) $1.619
(-0.14%) $2 343.80
(-1.29%) $27.18
(0.39%) $925.70
(-0.11%) $0.934
(-0.05%) $11.02
(-0.18%) $0.799
(0.00%) $92.17
Live Chart Being Loaded With Signals
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases...
Stats | |
---|---|
Dagens volum | 1.91M |
Gjennomsnittsvolum | 954 093 |
Markedsverdi | 6.57B |
EPS | $0 ( 2024-02-22 ) |
Neste inntjeningsdato | ( $0 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -66.29 |
ATR14 | $1.830 (1.06%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-09-26 | Desai Antal Rohit | Sell | 134 | Class A common stock |
2023-09-26 | Desai Antal Rohit | Sell | 993 929 | Class B common stock |
2023-09-26 | Mcgaughy R Kent Jr | Sell | 280 | Class A common stock |
2023-09-26 | Mcgaughy R Kent Jr | Sell | 278 309 | Class B common stock |
2023-09-26 | Mcgaughy R Kent Jr | Sell | 699 | Stock Option (right to buy) |
INSIDER POWER |
---|
-100.00 |
Last 100 transactions |
Buy: 0 | Sell: 4 695 639 |
Volum Korrelasjon
Reata Pharmaceuticals Inc Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
CREX | 0.957 |
MYRG | 0.875 |
ALLR | 0.869 |
MSSA | 0.849 |
SGEN | 0.847 |
NETE | 0.835 |
PLYA | 0.832 |
MHUA | 0.831 |
USAP | 0.83 |
SGTX | 0.825 |
10 Mest negative korrelasjoner | |
---|---|
RMGBU | -0.875 |
ENVI | -0.851 |
EJFA | -0.838 |
ONEM | -0.837 |
ESSA | -0.837 |
SVOK | -0.824 |
SAII | -0.819 |
FNCB | -0.818 |
BSBK | -0.816 |
PAIC | -0.814 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Reata Pharmaceuticals Inc Korrelasjon - Valuta/Råvare
Reata Pharmaceuticals Inc Økonomi
Annual | 2022 |
Omsetning: | $2.22M |
Bruttogevinst: | $2.22M (100.00 %) |
EPS: | $-8.59 |
FY | 2022 |
Omsetning: | $2.22M |
Bruttogevinst: | $2.22M (100.00 %) |
EPS: | $-8.59 |
FY | 2021 |
Omsetning: | $11.49M |
Bruttogevinst: | $11.49M (100.00 %) |
EPS: | $-8.19 |
FY | 2020 |
Omsetning: | $9.02M |
Bruttogevinst: | $9.02M (100.00 %) |
EPS: | $-7.35 |
Financial Reports:
No articles found.
Reata Pharmaceuticals Inc
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.